TH66198B - Pharmacodynamic constituents in the treatment of tissue damage Due to failure of the blood circulation of the aorta - Google Patents

Abstract

DC60 This invention is about human medicine. and especially containing pharmaceutical compounds made with Epidermal Growth Factor (EGF) and hexapeptide stimulating Growth Hormone secretagoge hexapeptide (GHRP); in defense tissue damage due to the pressure on blood circulation and in increasing tissue repair After the damage from the shortage of blood The aforementioned compounds may be used as a component on the other hand, the individual may receive both EGF and GHRP separately but in Single Therapeutic Schemes to Increase Cell Survival When organs lose blood circulation for a period of time during the crisis This combination reduced the generation of reactive oxygen species (ROS) and their relative cytotoxicity. This combination is useful in supplementing cell survival when tissue or organs exposed to prolonged blood shortage. The combination may be used as a prophylactic in people prone to multiple organ failure (MOF), such as those with burns, those with Sick with multiple wounds, hypoxia newborn, acute respiratory disease and patients with small intestine and ulcerative colitis, which causes tissue or cell death. This invention involves human medicine. and especially with pharmaceutical integration made with Epidermal growth factor (EGF) and selective hexapeptide Secretion of Growth Hormone (Growth Horrnone Sccrctagogehoxapertide) (GHRP) to prevent tissue damage due to the pressure on blood circulation and to increase tissue repair after damage from blood shortage The aforementioned inclusion May be used as a pharmaceutical mixture single science On the other hand, the person may receive both the EGE and the GHRP separately but in a different way. Single treatment to increase cell survival When organs lose blood circulation for a period of time a period of crisis This mixture reduces the generation of reactive oxygen species (ROS) and the relative cytotoxicity of that compound. The mixture is useful in enhancing the survival of cells when tissue or organs exposed to prolonged periods of blood shortage. Prophylactic form in people prone to multiple organ failure (MOF), such as those with burns, patients with multiple wounds, hypoxia newborns, and respiratory disease. Acute breathing and patients with small intestine and ulcerative colitis, which causes tissue or cell death. Patent drug

Claims (9)

1. Pharmacy mixtures Which is characterized by providing a peptide Which has the agility of Epidemnal Growth Factor in combination with hexapeptide That stimulate secretion Of growth hormoneseeretagotue hexapeptide (GHRP-6) for preventing and treating tissue damage This is due to lack of arterial blood flow and its consequences in animals and humans. 2. Pharmacodynamic mixtures according to claim 1, in which the epidider-active peptide Mol Rage Factor can be Epidermal Rage Factor (EGF), Transforming Growth Factor type alpha (TGF-Alpha) or Rage Factor. Heparin Binding EGF (Heparin Binding EGF-Like Growth Factor) (HB-EGF) 3. Pharmacy mixtures according to Clause 1, which the peptide with Epide agility. A Mol Rage Factor and Hexapeptide that stimulates the secretion of raging hormone GHRP-6 is a component of a single pharmacological compound with an additional appropriate exponent. Pharmacy according to claim 1, which provides a secretory-stimulating hexapeptide. Of the angry hormone GHRP-6 alone or in combination with the epidite-agile peptide Mol is angry with the patient's independent factor. As part of prevention or treatment 5. One of the Pharmacy Mixture according to Clause 1 to 4. Which the peptide has Epidermal rage factor is at a concentration of 0.5-50 μg / ml. When prepared in either solvent form or in iophilisation form 6. Pharmacy mixtures according to Clause 1 to 4, which Hexapeptide that Stimulate the secretion of the angry hormone GHRP-6 at a concentration of 2 y 100 μg / ml. When prepared in solution Or in the form of lyophilis. 7. Pharmacological compound according to Clause 1 to 6, any one Which must be given without passing A single dose of large intestine (bolnus) to provide defensive agility. Induced in a dose range of 0.5-1 μg of each active peptide per kilogram of body weight. 8. Pharmacodynamic mixtures according to Claim 1 to 6. Which must be provided in the form Sustained intravenous infusion for induction of transformation / regeneration in the 0.01 y 5 μg dose range of each active peptide per kg of patient body weight. 9. Pharmacodynamic mixtures. Which is characterized by the presence of hexapeptide that stimulates selective The secretion of the angry hormone GHRP-6 and the appropriate expectorant to induce protection against Damaged by lack of blood In order to prevent tissue damage When there is blood circulation Of the aorta fluids in humans and animals 1 0. Use of one of the pharmacological mixtures of claims 1 to 8 for the prevention of either serious or serious tissue damage. Or not in the affected tissue / or organ Affected by non-circulatory shortages, low circulation conditions, or deficiency / rehydration 1 1. The use of a pharmacokinetic mixture pursuant to one of Clause 1 to 8 of claim 1 to 8 for mitigation or correction of adjuvant treatment of adult respiratory distress (ARDS) 1. 2. The use of one of the Pharmacy Mixture according to Clause 1 to 8 for the prevention and correction of multiple organ dysfuncthin syndrome and related processes required for treatment. Strict supervision 1 3. The use of pharmaceutical mixtures according to claim 12 for the treatment of burned wounds, multiple trauma patients, wide area surgical patients, surgical patients. Implants, patients who have surgery with new tubes or tubes, patients who have been connected to Heart-Lung apparatus, Patients receiving thrombolytic and / or fibrinolysis treatment and recirculation, Crush syndromes, ischemic patients, shock , The productivity of the heart is low 1 4. Use of any one of Clause 1 to 8 of the Pharmacy Mixture to Adjuvant treatment for bleeding, abnormal fluid distribution, shock and deficiency. Blood / visceral passage of new fluids 1 5. Use of any Pharmacy Mixture according to Claim 1 to 8 as a Preventive Agent and a Pre-Used Substance for Transplant Surgery, Prolonged Blood Shortage Caused by Surgery. And one other condition that causes the early stages of blood shortage. Of internal organs Disease responsive to systemic inflammation And malfunctions of many organs 1 6. Use of the pharmaceutical mixture according to claim 15 to maintain the equilibrium of Internal environment of organs And internal membranes during surgery to have new tubes or tubes and to enhance the survival of any implants after transplantation such as kidneys, liver, pancreas, intestines, lungs, heart and skin plates 1 7. Use of any one of Clause 1 to 8 of the Pharmacy Mixture in the Prevention of Cell Damage. After any conditions which can impede the passage of membrane fluids with oxygenated blood 1 8. Use of any Pharmacy Mixture according to Clause 1 to 8. In acting Coordination through the functional patterns of tissues / organs After a case in which the results after that lead to death Of tissue Or group of cells 1 9. Use of any Pharmacy Mixture in accordance with Clause 1 to 8 for stimulation. Bowel adaptation processes After removal of part of the intestine, short bowel disease, bowel failure, etc., related or not related to total parpenteran nutrition.